Variable |
n |
% |
Range |
Median |
Age (years) |
|
|
47-83 |
68.7 |
iPSA (ng/ml) |
|
|
4.1-175.0 |
24.2 |
GS |
|
|
6-9 |
7 |
Follow up (Months) |
|
|
24-123 |
62.4 |
Last PSA |
|
|
0.01-99.7 |
3.4 |
Ethnicity |
|
|
|
|
Asiatic |
17 |
7.4 |
|
|
White |
181 |
79.0 |
|
|
Black |
18 |
7.9 |
|
|
Mulatto |
13 |
5.7 |
|
|
Clinical Stage |
|
|
|
|
T1 |
89 |
38.9 |
|
|
T2a |
71 |
31.0 |
|
|
T2b |
32 |
14.0 |
|
|
T3 |
37 |
16.2 |
|
|
Neo HT |
|
|
|
|
No |
123 |
53.7 |
|
|
Yes |
106 |
46.3 |
|
|
Adj HT |
|
|
|
|
No |
56 |
24.5 |
|
|
Yes |
173 |
75.5 |
|
|
Risk Group |
|
|
|
|
Intermediate |
117 |
51.1 |
|
|
High |
112 |
48.9 |
|
|
Total |
229 |
100.0 |
|
|
iPSA: Initial PSA Value; GS: Geason Score; IR: Intermediate Risk; HR: High
Risk; Neo HT: Neoadjuvant Androgen Deprivation; Adj HT: Adjuvant Androgen
Deprivation |